We are live on ! Find out more

884 hedge funds and large institutions have $72.3B invested in Biogen in 2014 Q4 according to their latest regulatory filings, with 130 funds opening new positions, 343 increasing their positions, 279 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more first-time investments, than exits

New positions opened: 130 | Existing positions closed: 54

27% more funds holding in top 10

Funds holding in top 10: 4152 (+11)

23% more repeat investments, than reductions

Existing positions increased: 343 | Existing positions reduced: 279

8% more funds holding

Funds holding: 818884 (+66)

2% more capital invested

Capital invested by funds: $71B → $72.3B (+$1.3B)

28% less call options, than puts

Call options by funds: $975M | Put options by funds: $1.36B

Holders
884
Holders Change
+66
Holders Change %
+8.07%
% of All Funds
23.57%
Holding in Top 10
52
Holding in Top 10 Change
+11
Holding in Top 10 Change %
+26.83%
% of All Funds
1.39%
New
130
Increased
343
Reduced
279
Closed
54
Calls
$975M
Puts
$1.36B
Net Calls
-$382M
Net Calls Change
+$97.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Advisers
126
Two Sigma Advisers
New York
$57.3M +$3.11M +9,600 +6%
GA
127
Geneva Advisors
Illinois
$56.9M +$12.4M +38,230 +30%
NA
128
Navellier & Associates
Nevada
$56.6M -$2.78M -8,596 -5%
1832 Asset Management
129
1832 Asset Management
Ontario, Canada
$56.3M -$95.7M -295,880 -64%
Comerica Bank
130
Comerica Bank
Texas
$54.5M +$25.2M +77,941 +94%
JIM
131
Jupiter Investment Management
United Kingdom
$54.1M +$26.6M +82,231 +107%
Canada Life
132
Canada Life
Manitoba, Canada
$53.4M -$746K -2,307 -1%
GIA
133
Gateway Investment Advisers
Ohio
$53.3M -$1.95M -6,031 -4%
ASC
134
Atalanta Sosnoff Capital
New York
$53.3M -$42.5M -131,443 -46%
Calamos Advisors
135
Calamos Advisors
Illinois
$52.6M -$533K -1,647 -1%
Los Angeles Capital Management
136
Los Angeles Capital Management
California
$52.5M +$28.3M +87,540 +130%
ACI
137
AMP Capital Investors
Australia
$51.9M -$8.42M -26,014 -15%
Stifel Financial
138
Stifel Financial
Missouri
$51.2M +$1.86M +5,736 +4%
UBS Group
139
UBS Group
Switzerland
$50.6M +$48.2M +148,965 New
DekaBank Deutsche Girozentrale
140
DekaBank Deutsche Girozentrale
Germany
$49.5M -$547K -1,692 -1%
QI
141
QS Investors
New York
$49.3M +$43.2M +133,588 +1,136%
CAM
142
Congress Asset Management
Massachusetts
$49.2M -$1.65M -5,094 -3%
Victory Capital Management
143
Victory Capital Management
Texas
$49.1M +$327K +1,012 +0.7%
HCM
144
Highbridge Capital Management
New York
$49M +$41.1M +126,935 +734%
MLICM
145
Metropolitan Life Insurance Company (MetLife)
New York
$47.7M -$159K -490 -0.3%
Fidelity International
146
Fidelity International
Bermuda
$47M +$19.3M +59,563 +76%
KBC Group
147
KBC Group
Belgium
$46.9M +$43.6M +134,623 +3,946%
Aviva
148
Aviva
United Kingdom
$45.8M +$6.46M +19,966 +17%
VanEck Associates
149
VanEck Associates
New York
$45.8M -$1.27M -3,925 -3%
Marshall Wace
150
Marshall Wace
United Kingdom
$45.4M +$39.1M +120,934 +935%

BIIB Hedge Fund Activity: Q4 2014 in Review

884 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2014, worth a combined $72.3B — up 1.8% from $71B a quarter earlier.

Buyers outnumbered sellers: 130 funds opened new BIIB positions and 54 closed out — a net gain of 76 holders — while 343 added to existing stakes and 279 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $326M. The largest seller was Capital Research Global Investors, cutting an estimated $1.67B.

  • 884 institutional investors held Biogen (BIIB) as of Q4 2014, up from 818 in Q3 2014.
  • Funds reported $72.3B of Biogen stock for Q4 2014, up 1.8% quarter-over-quarter.
  • 130 funds opened new Biogen positions in Q4 2014 and 54 closed out, a net change of +76 holders.
  • The largest Biogen buyer in Q4 2014 was Wellington Management Group, an estimated $326M added.
  • The largest Biogen seller in Q4 2014 was Capital Research Global Investors, an estimated $1.67B sold.

Based on aggregated 13F filings for Q4 2014.